Get a closer look at every layout included in the Montegrappa Template. Each homepage variation is designed for clarity, flexibility, and performance—so you can choose the one that best fits your needs.
Send us an email to lucas.gusso@gmail.com with your purchase receipt, and we will send you the editable Figma file for the Montegrappa Template.
State-Regulated Psilocybin Study for Veteran PTSD.
The clinical trials proved it works. Now we prove it works at scale.
Every day, over 44 veterans die by suicide in the United States. Not as a statistic, as fathers, mothers, daughters, sons. People who served with extraordinary courage and came home carrying wounds that conventional medicine was never fully able to heal.
.png)
Treatment-resistant PTSD is not a failure of willpower. It is a failure of tools. Landmark research from Johns Hopkins, NYU, and Imperial College London has demonstrated that psilocybin-assisted therapy produces profound, lasting relief in cases where decades of conventional treatment had failed.
FDA approval is now on the horizon. What comes next is the harder question: how does this treatment reach the millions who need it? Insurance coverage, VA adoption, and national healthcare integration all require one thing clinical trials cannot provide, rigorous, real-world outcomes data from inside an operational therapeutic system. That is precisely what this study is designed to produce.
Veterans with treatment-resistant PTSD
Psilocybin sessions per participant
Oral psilocybin dose, FDA Breakthrough Therapy
Oregon and Colorado's regulated frameworks
The Protocol
Half a Century of Research. One Question Remaining.
Psilocybin has been designated an FDA Breakthrough Therapy for PTSD and depression. Landmark studies at Johns Hopkins, NYU Langone, and Imperial College London have demonstrated rapid, durable symptom reduction, in many cases after just one or two sessions. A 2021 Johns Hopkins study found a 54% reduction in depression scores sustained at 12-month follow-up.
Every one of those trials was conducted in a controlled clinical setting with highly screened participants. None has answered the question that now stands between approval and access: do these results hold inside a real-world, state-regulated therapeutic system, with the broader veteran population that needs it most?
As the only research institution embedded within Oregon and Colorado's regulated programs from their inception, CIRC is uniquely positioned to generate the outcomes data that insurers, the VA, and healthcare systems need to make this treatment broadly accessible.
.png)
Figure 1. CONSORT Diagram of Participant Flow. Source: Davis AK, Barrett FS, May DG, et al. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2021;78(5):481–489. doi:10.1001/jamapsychiatry.2020.3285. CIRC's veteran PTSD study follows the same rigorous screening standards.
A Structured Path to Healthcare Integration
Protocol Development: Team assembled. Site agreements in place.
This Study Doesn't End With 30 Veterans. It Begins There.
FDA approval opens the door. Insurance coverage, VA adoption, and scalable access require a different kind of evidence, not what psilocybin can do in a clinical trial, but what it delivers inside a real-world system of care.
The data generated here becomes the first state-regulated, real-world psilocybin PTSD outcomes dataset in U.S. history. It travels directly to the conversations that determine whether this treatment reaches the millions who need it, payers, the VA, and the healthcare systems building the next standard of care.
When you fund this study, you are not writing a check to a research lab. You are writing the first chapter of a new system of care.
Every Dollar Has a Job.
Facilitator time, sessions, healing center fees, and psilocybin for all 30 veterans.
Principal investigator, research coordinators, IRB compliance, and two years of study administration.
Machine learning processing, peer-reviewed publication, and open-access distribution to policymakers and clinicians.